These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. A dopamine receptor antagonist L-745,870 suppresses microglia activation in spinal cord and mitigates the progression in ALS model mice. Tanaka K, Okada Y, Kanno T, Otomo A, Yanagisawa Y, Shouguchi-Miyata J, Suga E, Kohiki E, Onoe K, Osuga H, Aoki M, Hadano S, Itoyama Y, Ikeda JE. Exp Neurol; 2008 Jun; 211(2):378-86. PubMed ID: 18423451 [Abstract] [Full Text] [Related]
12. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease. Gil JM, Rego AC. Brain Res Rev; 2009 Mar; 59(2):410-31. PubMed ID: 19118572 [Abstract] [Full Text] [Related]
14. Systemic administration of Congo red does not improve motor or cognitive function in R6/2 mice. Wood NI, Pallier PN, Wanderer J, Morton AJ. Neurobiol Dis; 2007 Feb; 25(2):342-53. PubMed ID: 17095235 [Abstract] [Full Text] [Related]
15. IGF-1 exacerbates the neurotoxicity of the mitochondrial inhibitor 3NP in rats. Escartin C, Boyer F, Bemelmans AP, Hantraye P, Brouillet E. Neurosci Lett; 2007 Oct 02; 425(3):167-72. PubMed ID: 17868993 [Abstract] [Full Text] [Related]
17. The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase. Bailey CD, Johnson GV. Neurobiol Aging; 2006 Jun 02; 27(6):871-9. PubMed ID: 15896882 [Abstract] [Full Text] [Related]